Q-omics provides the consensus-scored U2AF1L5 profile across patient tissues and cancer cell-line models. U2AF1L5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, U2AF1L5 is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, U2AF1L5 RNA expression shows 6,131 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight COAD, LUSC, and KIRC as cancer lineages where U2AF1L5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for U2AF1L5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes U2AF1L5 survival associations across molecular data types. U2AF1L5 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible U2AF1L5 RNA expression–survival associations across cancer types. High U2AF1L5 expression shows unfavorable associations in COAD, READ, OV and ACC, but favorable associations in UCS and ESCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify COAD as the clearest survival context for U2AF1L5 RNA expression.
This table summarizes U2AF1L5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for U2AF1L5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. U2AF1L5 shows lower tumor expression in LUSC and COAD and higher tumor expression in LIHC and KIRC. The LUSC box plot shows higher U2AF1L5 RNA expression in normal versus tumor tissue (log2 FC = −0.112, t-test p = .045).
This table shows molecular features associated with U2AF1L5 in patient tissues and cancer cell lines. In patient samples, U2AF1L5 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set. In cancer cell lines, U2AF1L5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma.
